# Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events

> **NCT00206089** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 3300 (—)

## Conditions studied

- Thromboembolism

## Interventions

- **DRUG:** EXANTA

## Key facts

- **NCT ID:** NCT00206089
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 3300 (—)
- **Why stopped:** Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety.
- **Last updated:** 2010-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206089, "Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00206089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*